Autophagy-dependent danger signaling and adaptive immunity to poorly immunogenic tumors

Guido Kroemer; Lorenzo Galluzzi

doi:10.18632/oncotarget.13892

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

Autophagy-dependent danger signaling and adaptive immunity to poorly immunogenic tumors

Guido Kroemer and Lorenzo Galluzzi _

PDF | HTML | How to cite

Oncotarget. 2017; 8:5686-5691. https://doi.org/10.18632/oncotarget.13892

Metrics: PDF 2463 views | HTML 2847 views | ?

Abstract

Guido Kroemer1,2,3,4,5,6,7 and Lorenzo Galluzzi1,2,3,4,8,9

1 Equipe 11 Labellisée par la Ligue Contre le Cancer, Centre de Recherche des Cordeliers, Paris, France

2 INSERM, U1138, Paris, France

3 Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France

4 Université Pierre et Marie Curie/Paris VI, Paris, France

5 Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France

6 Pôle de Biologie, Hopitâl Européen George Pompidou, AP-HP, Paris, France

7 Department of Women’s and Children’s Health, Karolinska University Hospital, Stockholm, Sweden

8 Gustave Roussy Comprehensive Cancer Institute, Villejuif, France

9 Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA

Correspondence to:

Lorenzo Galluzzi, email:

Keywords: ATP; chloroquine; damage-associated molecular patterns; doxorubicin; immunogenic cell death; radiation therapy

Received: October 27, 2016 Accepted: November 14, 2016 Published: December 10, 2016

Abstract

Recent data suggest that autophagy does not influence spontaneous and therapy-elicited tumor infiltration by immune cells in murine models of melanoma and breast carcinoma. These findings, which have been obtained in the absence of a therapeutically relevant anticancer immune response, indicate that the intrinsically low immunogenicity of some tumors cannot be compensated for by increased danger signaling.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13892

Publication Alerts

Oncoscience

Post-Publication Promotion

Research Perspectives:

Autophagy-dependent danger signaling and adaptive immunity to poorly immunogenic tumors

Abstract